These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

222 related articles for article (PubMed ID: 11351352)

  • 1. Naturally occurring prostate cancer antigen-specific T cell responses of a Th1 phenotype can be detected in patients with prostate cancer.
    McNeel DG; Nguyen LD; Ellis WJ; Higano CS; Lange PH; Disis ML
    Prostate; 2001 May; 47(3):222-9. PubMed ID: 11351352
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Identification of T helper epitopes from prostatic acid phosphatase.
    McNeel DG; Nguyen LD; Disis ML
    Cancer Res; 2001 Jul; 61(13):5161-7. PubMed ID: 11431355
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Differential CTLs specific for prostate-specific antigen in healthy donors and patients with prostate cancer.
    Elkord E; Williams PE; Kynaston H; Rowbottom AW
    Int Immunol; 2005 Oct; 17(10):1315-25. PubMed ID: 16141246
    [TBL] [Abstract][Full Text] [Related]  

  • 4. High frequency of prostate antigen-directed T cells in cancer patients compared to healthy age-matched individuals.
    Forsberg O; Carlsson B; Malmström PU; Ullenhag G; Tötterman TH; Essand M
    Prostate; 2009 Jan; 69(1):70-81. PubMed ID: 18814178
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antibody and T-cell responses specific for the androgen receptor in patients with prostate cancer.
    Olson BM; McNeel DG
    Prostate; 2007 Dec; 67(16):1729-39. PubMed ID: 17879963
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Identification of HLA-DRB1*1501-restricted T-cell epitopes from prostate-specific antigen.
    Klyushnenkova EN; Link J; Oberle WT; Kodak J; Rich C; Vandenbark AA; Alexander RB
    Clin Cancer Res; 2005 Apr; 11(8):2853-61. PubMed ID: 15837732
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Cryoablation for prostate cancer induces tumor-specific immune response].
    Si TG; Guo Z; Wang HT; Han YP; Hao XS
    Zhonghua Nan Ke Xue; 2009 Apr; 15(4):350-3. PubMed ID: 19472911
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Presence and specificity of tumor associated lymphocytes from ascites fluid in prostate cancer.
    Ozenci V; Miller AM; Palmborg A; Egevad L; Jaremko GA; Kälkner KM; Pisa P
    Prostate; 2005 Sep; 65(1):20-6. PubMed ID: 15800933
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prostate-specific antigen-derived epitopes capable of inducing cellular and humoral responses in HLA-A24+ prostate cancer patients.
    Harada M; Kobayashi K; Matsueda S; Nakagawa M; Noguchi M; Itoh K
    Prostate; 2003 Oct; 57(2):152-9. PubMed ID: 12949939
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Induction of immune responses and safety profiles in rhesus macaques immunized with a DNA vaccine expressing human prostate specific antigen.
    Kim JJ; Yang JS; Nottingham LK; Tang W; Dang K; Manson KH; Wyand MS; Wilson DM; Weiner DB
    Oncogene; 2001 Jul; 20(33):4497-506. PubMed ID: 11494145
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Human CTL epitopes prostatic acid phosphatase-3 and six-transmembrane epithelial antigen of prostate-3 as candidates for prostate cancer immunotherapy.
    Machlenkin A; Paz A; Bar Haim E; Goldberger O; Finkel E; Tirosh B; Volovitz I; Vadai E; Lugassy G; Cytron S; Lemonnier F; Tzehoval E; Eisenbach L
    Cancer Res; 2005 Jul; 65(14):6435-42. PubMed ID: 16024648
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Identification and characterization of a human agonist cytotoxic T-lymphocyte epitope of human prostate-specific antigen.
    Terasawa H; Tsang KY; Gulley J; Arlen P; Schlom J
    Clin Cancer Res; 2002 Jan; 8(1):41-53. PubMed ID: 11801539
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A modified epitope identified for generation and monitoring of PSA-specific T cells in patients on early phases of PSA-based immunotherapeutic protocols.
    Lundberg K; Roos AK; Pavlenko M; Leder C; Wehrum D; Guevara-Patiño J; Andersen RS; Pisa P
    Vaccine; 2009 Mar; 27(10):1557-65. PubMed ID: 19171173
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Specific antitumor immune response induced by a novel DNA vaccine composed of multiple CTL and T helper cell epitopes of prostate cancer associated antigens.
    Qin H; Zhou C; Wang D; Ma W; Liang X; Lin C; Zhang Y; Zhang S
    Immunol Lett; 2005 Jun; 99(1):85-93. PubMed ID: 15894116
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Analysis and characterization of antitumor T-cell response after administration of dendritic cells loaded with allogeneic tumor lysate to metastatic melanoma patients.
    Bercovici N; Haicheur N; Massicard S; Vernel-Pauillac F; Adotevi O; Landais D; Gorin I; Robert C; Prince HM; Grob JJ; Leccia MT; Lesimple T; Wijdenes J; Bartholeyns J; Fridman WH; Salcedo M; Ferries E; Tartour E
    J Immunother; 2008 Jan; 31(1):101-12. PubMed ID: 18157017
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Molecular and immunological analysis of genetic prostate specific antigen (PSA) vaccine.
    Kim JJ; Trivedi NN; Wilson DM; Mahalingam S; Morrison L; Tsai A; Chattergoon MA; Dang K; Patel M; Ahn L; Boyer JD; Chalian AA; Schoemaker H; Kieber-Emmons T; Agadjanyan MA; Weiner DB
    Oncogene; 1998 Dec; 17(24):3125-35. PubMed ID: 9872328
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Disease-stage variance in functional CD4(+) T-cell responses against novel pan-human leukocyte antigen-D region presented human papillomavirus-16 E7 epitopes.
    Warrino DE; Olson WC; Knapp WT; Scarrow MI; D'Ambrosio-Brennan LJ; Guido RS; Edwards RP; Kast WM; Storkus WJ
    Clin Cancer Res; 2004 May; 10(10):3301-8. PubMed ID: 15161683
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Construction and in vivo evaluation of an anti-PSA x anti-CD3 bispecific antibody for the immunotherapy of prostate cancer.
    Katzenwadel A; Schleer H; Gierschner D; Wetterauer U; Elsässer-Beile U
    Anticancer Res; 2000; 20(3A):1551-5. PubMed ID: 10928069
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Induction of gamma delta T cells using zoledronate plus interleukin-2 in patients with metastatic cancer.
    Nagamine I; Yamaguchi Y; Ohara M; Ikeda T; Okada M
    Hiroshima J Med Sci; 2009 Mar; 58(1):37-44. PubMed ID: 19400555
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Allogeneic retrovirally transduced, IL-2- and IFN-gamma-secreting cancer cell vaccine in patients with hormone refractory prostate cancer--a phase I clinical trial.
    Brill TH; Kübler HR; von Randenborgh H; Fend F; Pohla H; Breul J; Hartung R; Paul R; Schendel DJ; Gansbacher B
    J Gene Med; 2007 Jul; 9(7):547-60. PubMed ID: 17514769
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.